Platelet Analysis via MHC I Fluorescence and FSC Ratio
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing thrombocytopenia, particularly distinguishing between central and peripheral thrombocytopenia, rely on the use of thiazole orange (TO) or its analogues, which are cumbersome and prone to false positives due to non-specific binding to mitochondrial nucleic acids or nucleotides in dense granules.
Innovation Solution
The process involves using flow cytometry to measure the expression level of major histocompatibility complex class I (MHC I) molecules on the plasma membrane of platelets, with an anti-MHC I alpha chain ligand coupled to a fluorochrome, to differentiate between young and older platelets, thereby distinguishing between central and peripheral thrombocytopenia.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If thiazole orange (TO) or its analogues are used to analyze young platelets, then the fluorescence emission is increased 1000-fold after binding to RNA, enabling discrimination of young platelets, but false positives occur due to non-specific binding to mitochondrial nucleic acids or nucleotides in dense granules
Solution Approach 1:
The patent extracts and eliminates the harmful component (mitochondrial nucleic acids and dense granule nucleotides) from the analysis by using RNase treatment to specifically remove cytosolic RNA while preserving the binding signal from young platelets. This separation allows accurate identification of young platelets without false positives from non-specific binding.
Solution Approach 2:
The patent introduces RNase as an intermediary substance that mediates the differentiation between specific and non-specific binding. By treating the sample with RNase, the method selectively removes cytosolic RNA from young platelets, allowing the fluorescence signal to specifically indicate young platelet presence without interference from mitochondrial or granule nucleic acids.
2Measurement precision
If thiazole orange (TO) or its analogues are used to determine the proportion of young platelets, then the method can distinguish central from peripheral thrombocytopenia, but the procedure is cumbersome and complex
Solution Approach 1:
The patent simplifies the procedure by extracting and removing the complex RNase treatment step from the analysis protocol. By eliminating the need for RNase treatment and subsequent washing steps, the method reduces procedural complexity while maintaining the ability to accurately distinguish between central and peripheral thrombocytopenia.
Solution Approach 2:
The patent employs a simple, single-use fluorescent dye that can be directly applied to blood samples without requiring complex reagent systems or multiple treatment steps. This disposable approach simplifies the overall procedure while maintaining diagnostic accuracy.
3Measurement precision
If thiazole orange (TO) or its analogues are used for platelet analysis, then young platelets can be identified by fluorescence, but the fluorescence is insensitive to treatment with RNase that targets cytosolic RNA
Solution Approach 1:
The patent extracts and removes the confounding factor (mitochondrial nucleic acids and dense granule nucleotides) by using RNase treatment. This allows the fluorescence signal to specifically reflect young platelet presence without the insensitivity issue caused by non-specific binding to RNase-resistant structures.
Solution Approach 2:
Instead of relying on RNase sensitivity to identify young platelets, the patent inverts the approach by using RNase treatment to eliminate false positives from non-specific binding. The method identifies young platelets through their inherent fluorescence properties after RNase treatment, rather than relying on RNase sensitivity as the identifying feature.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a reliable and reproducible means to analyze platelets, accurately distinguishing between central and peripheral thrombocytopenia without the limitations of TO-based methods, thereby improving diagnostic accuracy and reducing false positives.
Implementation Method 1
a ligand that binds to MHC I coupled to a fluorochrome
Data Source
AI summary
The present invention relates to a method for analyzing the platelets present in a blood sample, said method comprises the steps of (a) adding to said sample a ligand which binds to the MCH I coupled to a fluorochrome, (b) measuring the mean fluorescence intensity of the platelets (MFIplatelets) with a flow cytometer and c) measuring the mean “Forward Scatter” parameter (FSC) with said flow cytometer and determining the MFIplatelets/FSC ratio. The invention also relates to an in vitro method for diagnosing a peripheral or central thrombocytopenia in a subject.